Skip to main content

Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

Objective

Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to improve the safety, cost-effectiveness and patient acceptability for the treatment of wet age-related macular degeneration (AMD). AMD is the leading cause of blindness in those aged over 50 and causes blurring, distortion and loss of central vision and almost always affects quality of life. Prototype SR Bevacizumab products will be manufactured using CriticalMix, an advanced manufacturing and processing technology developed by Critical Pharmaceuticals, which will encapsulate bevacizumab in biodegradable polymers suitable for sustained release of the drug in the eye.

Field of science

  • /natural sciences/chemical sciences/polymer science
  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /medical and health sciences/clinical medicine/ophthalmology

Call for proposal

H2020-SMEINST-1-2014
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

CRITICAL PHARMACEUTICALS LIMITED
Address
Biocity Nottingham - Pennyfoot Street
NG1 1GF Nottingham
United Kingdom
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000